Tango Therapeutics, Inc.
TNGX
株式のランク
#4544
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
株価
$27.18
最終同期: 2026-07-31
時価総額
$3.38B
変化（1日）
-1.41%
変化（1年）
202.34%
国
US
取引 Tango Therapeutics, Inc. (TNGX)
カテゴリー
Healthcare
Tango Therapeutics, Inc.（TNGX）の発行済株式数
June 2026 時点の発行済株式数 149.88M
Tango Therapeutics, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 149.88M です。December 2023 の終わりには、同社は 94.57M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Tango Therapeutics, Inc.（TNGX）の発行済株式数の履歴（2019 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 149.88M | 37.22% |
| 2024 | 109.23M | 15.50% |
| 2023 | 94.57M | 7.69% |
| 2022 | 87.82M | 41.40% |
| 2021 | 62.11M | -29.00% |
| 2020 | 87.47M | 0.00% |
| 2019 | 87.47M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 69.41% |
US
|
|
| 396.00M | 164.22% |
US
|
|
| 478.91M | 219.54% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -58.51% |
NL
|
